Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven). Tosco L, et al. Among authors: de meerleer g. BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z. BMC Cancer. 2018. PMID: 29606109 Free PMC article.
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial.
Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W, Dirix P, Van den Bergh L, Crijns W, Vandendriessche H, Van Wynsberge L, Ost P, Lumen N, Buelens P, Haustermans K, Berghen C, De Meerleer G. Draulans C, et al. Among authors: de meerleer g. JMIR Res Protoc. 2018 Dec 13;7(12):e11256. doi: 10.2196/11256. JMIR Res Protoc. 2018. PMID: 30545809 Free PMC article.
Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, Berghen C, Everaerts W, Albersen M, Tsaturyan A, De Meerleer G, Van Poppel H, Goffin K, Ost P, Tosco L, Joniau S. Battaglia A, et al. Among authors: de meerleer g. World J Urol. 2019 Aug;37(8):1543-1549. doi: 10.1007/s00345-019-02716-8. Epub 2019 Mar 12. World J Urol. 2019. PMID: 30859274
Correction to: Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.
Battaglia A, Devos G, Decaestecker K, Witters M, Moris L, Van den Broeck T, Berghen C, Everaerts W, Albersen M, Tsaturyan A, De Meerleer G, Van Poppel H, Goffin K, Ost P, Tosco L, Joniau S. Battaglia A, et al. Among authors: de meerleer g. World J Urol. 2020 Jun;38(6):1589. doi: 10.1007/s00345-020-03172-5. World J Urol. 2020. PMID: 32221712
Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments.
Devos G, Witters M, Moris L, Van den Broeck T, Berghen C, Devlies W, De Meerleer G, Goffin K, Jentjens S, Albersen M, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Among authors: de meerleer g. World J Urol. 2021 Feb;39(2):399-406. doi: 10.1007/s00345-020-03220-0. Epub 2020 May 16. World J Urol. 2021. PMID: 32417995
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer.
Ahmadi Bidakhvidi N, Laenen A, Jentjens S, Deroose CM, Van Laere K, De Wever L, Mai C, Berghen C, De Meerleer G, Haustermans K, Joniau S, Everaerts W, Goffin K. Ahmadi Bidakhvidi N, et al. Among authors: de wever l, de meerleer g. EJNMMI Res. 2021 Apr 30;11(1):41. doi: 10.1186/s13550-021-00783-w. EJNMMI Res. 2021. PMID: 33929626 Free PMC article.
202 results